Compugen to Participate in Upcoming Investor Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 hours ago
0mins
Should l Buy CGEN?
Source: PRnewswire
- Investor Conference Schedule: Compugen will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, in a virtual format featuring fireside chats and one-on-one meetings, which is expected to draw investor interest in its clinical-stage cancer immunotherapy.
- Timing and Location: Following the Oppenheimer event, Compugen will also attend the Leerink Partners 2026 Global Healthcare Conference in Miami, Florida, on March 9, 2026, with the fireside chat scheduled for 8:40 AM ET, further enhancing the company's visibility among investors.
- Technological Platform Advantage: Compugen leverages its AI/ML-powered computational discovery platform, Unigen™, focusing on identifying novel drug targets and biological pathways to advance cancer immunotherapy development, showcasing its technological leadership in the industry.
- Clinical Pipeline Progress: The company has multiple clinical-stage projects, including COM902 and rilvegostomig targeting TIGIT, with the latter being developed by AstraZeneca in Phase 3, indicating Compugen's innovative potential and competitive edge in cancer treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CGEN
Wall Street analysts forecast CGEN stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.700
Low
4.00
Averages
4.00
High
4.00
Current: 1.700
Low
4.00
Averages
4.00
High
4.00
About CGEN
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Compugen to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Compugen will announce its fourth quarter and full year 2025 financial results on March 2, 2026, before the U.S. markets open, which is expected to provide investors with critical financial data and operational updates.
- Conference Call Details: Management will host a conference call and webcast at 8:30 AM ET, with investors able to join by dialing 1-866-744-5399 in the U.S. or +972-3-918-0644 internationally, ensuring broad investor participation.
- Technology Platform Overview: Compugen utilizes its AI/ML-powered computational discovery platform (Unigen™) to identify novel drug targets and biological pathways, focusing on developing cancer immunotherapies, showcasing its innovative capabilities at the clinical stage.
- Pipeline Summary: The company has multiple Fc-reduced programs targeting TIGIT, including COM902 and rilvegostomig, the latter being developed in Phase 3 by AstraZeneca, indicating Compugen's strategic collaboration potential in cancer treatment.
See More
Compugen to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Compugen will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, in a virtual format featuring fireside chats and one-on-one meetings, which is expected to draw investor interest in its clinical-stage cancer immunotherapy.
- Timing and Location: Following the Oppenheimer event, Compugen will also attend the Leerink Partners 2026 Global Healthcare Conference in Miami, Florida, on March 9, 2026, with the fireside chat scheduled for 8:40 AM ET, further enhancing the company's visibility among investors.
- Technological Platform Advantage: Compugen leverages its AI/ML-powered computational discovery platform, Unigen™, focusing on identifying novel drug targets and biological pathways to advance cancer immunotherapy development, showcasing its technological leadership in the industry.
- Clinical Pipeline Progress: The company has multiple clinical-stage projects, including COM902 and rilvegostomig targeting TIGIT, with the latter being developed by AstraZeneca in Phase 3, indicating Compugen's innovative potential and competitive edge in cancer treatment.
See More
Compugen Appoints New Independent Director
- New Board Member: Compugen appointed Dr. Michele Holcomb as an independent director effective February 11, 2026, bringing over 30 years of experience in biotech and pharmaceuticals, which is expected to enhance the board's strategic guidance and innovation capabilities.
- Financial Strength Context: Entering 2026, Compugen is in a position of financial strength with multiple potential first-in-class clinical programs and two validating pharma partnerships, and Holcomb's expertise will help convert these opportunities into long-term value.
- Rich Industry Experience: Previously serving as Chief Strategy Officer at Cardinal Health, Holcomb defined strategies and optimized portfolios, and her extensive experience in various executive roles will provide crucial support for Compugen's innovation and growth.
- Strategic Partnership Potential: Holcomb's deep background in biotechnology and insights into the healthcare industry will assist Compugen in identifying and seizing new growth opportunities in a competitive market, driving the company's continued success.
See More
HC Wainwright Initiates Buy on Jade Biosciences with $25 Price Target
- Rating Initiation: HC Wainwright & Co. analyst Arthur He initiated coverage on Jade Biosciences Inc (NASDAQ:JBIO) with a Buy rating and a price target of $25, reflecting confidence in the company's future growth potential.
- Market Performance: Jade Biosciences shares closed at $13.17 on Tuesday, and the analyst's target price implies an upside of over 89%, which could attract more investor interest in the stock.
- Industry Outlook: With the ongoing development in the biotech sector, Jade Biosciences' new products and technologies are expected to drive market share growth, and the positive rating may further enhance market confidence in the company.
- Investor Attention: The analyst's Buy rating and high price target could prompt more institutional investors to consider increasing their positions in the stock, thereby enhancing its liquidity and market recognition.
See More
Compugen Agrees with AstraZeneca to Monetize Future Royalties of Rilvegostomig
- Financial Strengthening: Compugen's agreement with AstraZeneca to monetize future royalties from rilvegostomig is expected to enhance its financial position, extending its cash runway into 2029 and providing ongoing support for its innovative immuno-oncology pipeline.
- Strategic Collaboration: The amended exclusive license agreement aims to bolster Compugen's capabilities in immuno-oncology, reflecting the significant potential value of rilvegostomig and further solidifying the company's market position in cancer treatment.
- Pipeline Expansion: Rilvegostomig, a PD-1/TIGIT bispecific antibody developed in collaboration with AstraZeneca, is currently in Phase 3 development, highlighting its importance in clinical trials and potential as a key future product.
- Innovative Platform Utilization: Compugen leverages its AI/ML-powered computational discovery platform (Unigen™) to identify novel drug targets, advancing the development of immunotherapies and showcasing the company's technological advantages and market potential in cancer treatment.
See More
Compugen Secures $65 Million Upfront Payment in AstraZeneca Deal
- Capital Injection: Compugen's agreement with AstraZeneca secures a $65 million upfront payment, with an additional $25 million contingent on the next milestone, significantly enhancing the company's financial position and extending its cash runway into 2029.
- Royalty Retention: By retaining the majority of future royalties, Compugen ensures potential earnings of up to $195 million from rilvegostomig's success, reflecting the company's confidence in the product and providing long-term value for shareholders.
- Pipeline Advancement: This transaction supports the advancement of Compugen's innovative immuno-oncology pipeline, enabling the company to continue developing unique therapeutic solutions while maintaining significant upside from rilvegostomig's potential success.
- Market Outlook: As a first-in-class dual-checkpoint inhibitor undergoing 11 Phase 3 trials, rilvegostomig presents substantial market opportunities for Compugen, further solidifying its leadership position in the cancer immunotherapy sector.
See More
Compugen to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Compugen will announce its fourth quarter and full year 2025 financial results on March 2, 2026, before the U.S. markets open, which is expected to provide investors with critical financial data and operational updates.
- Conference Call Details: Management will host a conference call and webcast at 8:30 AM ET, with investors able to join by dialing 1-866-744-5399 in the U.S. or +972-3-918-0644 internationally, ensuring broad investor participation.
- Technology Platform Overview: Compugen utilizes its AI/ML-powered computational discovery platform (Unigen™) to identify novel drug targets and biological pathways, focusing on developing cancer immunotherapies, showcasing its innovative capabilities at the clinical stage.
- Pipeline Summary: The company has multiple Fc-reduced programs targeting TIGIT, including COM902 and rilvegostomig, the latter being developed in Phase 3 by AstraZeneca, indicating Compugen's strategic collaboration potential in cancer treatment.
See More
Compugen to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Compugen will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, in a virtual format featuring fireside chats and one-on-one meetings, which is expected to draw investor interest in its clinical-stage cancer immunotherapy.
- Timing and Location: Following the Oppenheimer event, Compugen will also attend the Leerink Partners 2026 Global Healthcare Conference in Miami, Florida, on March 9, 2026, with the fireside chat scheduled for 8:40 AM ET, further enhancing the company's visibility among investors.
- Technological Platform Advantage: Compugen leverages its AI/ML-powered computational discovery platform, Unigen™, focusing on identifying novel drug targets and biological pathways to advance cancer immunotherapy development, showcasing its technological leadership in the industry.
- Clinical Pipeline Progress: The company has multiple clinical-stage projects, including COM902 and rilvegostomig targeting TIGIT, with the latter being developed by AstraZeneca in Phase 3, indicating Compugen's innovative potential and competitive edge in cancer treatment.
See More
Compugen Appoints New Independent Director
- New Board Member: Compugen appointed Dr. Michele Holcomb as an independent director effective February 11, 2026, bringing over 30 years of experience in biotech and pharmaceuticals, which is expected to enhance the board's strategic guidance and innovation capabilities.
- Financial Strength Context: Entering 2026, Compugen is in a position of financial strength with multiple potential first-in-class clinical programs and two validating pharma partnerships, and Holcomb's expertise will help convert these opportunities into long-term value.
- Rich Industry Experience: Previously serving as Chief Strategy Officer at Cardinal Health, Holcomb defined strategies and optimized portfolios, and her extensive experience in various executive roles will provide crucial support for Compugen's innovation and growth.
- Strategic Partnership Potential: Holcomb's deep background in biotechnology and insights into the healthcare industry will assist Compugen in identifying and seizing new growth opportunities in a competitive market, driving the company's continued success.
See More
HC Wainwright Initiates Buy on Jade Biosciences with $25 Price Target
- Rating Initiation: HC Wainwright & Co. analyst Arthur He initiated coverage on Jade Biosciences Inc (NASDAQ:JBIO) with a Buy rating and a price target of $25, reflecting confidence in the company's future growth potential.
- Market Performance: Jade Biosciences shares closed at $13.17 on Tuesday, and the analyst's target price implies an upside of over 89%, which could attract more investor interest in the stock.
- Industry Outlook: With the ongoing development in the biotech sector, Jade Biosciences' new products and technologies are expected to drive market share growth, and the positive rating may further enhance market confidence in the company.
- Investor Attention: The analyst's Buy rating and high price target could prompt more institutional investors to consider increasing their positions in the stock, thereby enhancing its liquidity and market recognition.
See More
Compugen Agrees with AstraZeneca to Monetize Future Royalties of Rilvegostomig
- Financial Strengthening: Compugen's agreement with AstraZeneca to monetize future royalties from rilvegostomig is expected to enhance its financial position, extending its cash runway into 2029 and providing ongoing support for its innovative immuno-oncology pipeline.
- Strategic Collaboration: The amended exclusive license agreement aims to bolster Compugen's capabilities in immuno-oncology, reflecting the significant potential value of rilvegostomig and further solidifying the company's market position in cancer treatment.
- Pipeline Expansion: Rilvegostomig, a PD-1/TIGIT bispecific antibody developed in collaboration with AstraZeneca, is currently in Phase 3 development, highlighting its importance in clinical trials and potential as a key future product.
- Innovative Platform Utilization: Compugen leverages its AI/ML-powered computational discovery platform (Unigen™) to identify novel drug targets, advancing the development of immunotherapies and showcasing the company's technological advantages and market potential in cancer treatment.
See More
Compugen Secures $65 Million Upfront Payment in AstraZeneca Deal
- Capital Injection: Compugen's agreement with AstraZeneca secures a $65 million upfront payment, with an additional $25 million contingent on the next milestone, significantly enhancing the company's financial position and extending its cash runway into 2029.
- Royalty Retention: By retaining the majority of future royalties, Compugen ensures potential earnings of up to $195 million from rilvegostomig's success, reflecting the company's confidence in the product and providing long-term value for shareholders.
- Pipeline Advancement: This transaction supports the advancement of Compugen's innovative immuno-oncology pipeline, enabling the company to continue developing unique therapeutic solutions while maintaining significant upside from rilvegostomig's potential success.
- Market Outlook: As a first-in-class dual-checkpoint inhibitor undergoing 11 Phase 3 trials, rilvegostomig presents substantial market opportunities for Compugen, further solidifying its leadership position in the cancer immunotherapy sector.
See More
